• Vol. 51 No. 7, 441–443
  • 28 July 2022

Iatrogenic atrial septal defect after catheter ablation—to close or not to close?


0 Citing Article

Download PDF

Dear Editor,

Transseptal access to the left heart is increasingly performed for electrophysiological procedures and for structural heart disease interventions such as balloon mitral valvuloplasty (BMV), left atrial appendage closure (LAAC) and transcatheter mitral valve repair (TMVr). Most of the iatrogenic atrial septal defects (iASDs) close spontaneously, and for those that persist, the majority do not result in clinical manifestations.1 Infrequently, a clinically significant interatrial shunt persists; mostly left to right, resulting in right heart failure.2 We report an unusual case of arterial desaturation due to right-to-left interatrial shunting following transseptal access for electrophysiological ablation, which was successfully treated with device closure.

Case report. A 69-year-old woman presented with increasing dyspnoea (New York Heart Association [NYHA] class III) of 4 months’ duration. She had a history of myocarditis and cardiogenic shock with severely impaired left ventricular ejection fraction (LVEF) of 20–25% 3 years prior, which required extracorporeal membrane oxygenator and intra-aortic balloon pump support, and insertion of an implantable cardioverter-defibrillator (ICD). She recovered with a mildly impaired LVEF of 40–45%.

Six months before the current presentation, she experienced increasing episodes of ventricular tachycardia (VT) that required ICD anti-tachycardia pacing and shocks despite maximal therapy with amiodarone and bisoprolol. Echocardiography revealed a LVEF of 40–45%, bileaflet mitral valve prolapse, moderate to severe mitral regurgitation (MR), dilated tricuspid annulus with severe tricuspid regurgitation (TR) and severely dilated atria. Mean pulmonary artery pressure (PAP) was 24mmHg.

However, 2 months after the ablation procedure, she developed increasing dyspnoea with minimal exertion (NYHA class III). Optimising her medications did not alleviate her symptoms and her oxygen saturation was 88–89% despite use of supplemental oxygen. Repeat echocardiography showed unchanged LVEF, MR and TR, and mean PAP was 30mmHg; however, there was a right-to-left shunt across the iASD. It was noted that the TR jet was eccentric and was directed towards the atrial septum. Subsequent transoesophageal echocardiogram (TEE) confirmed a right-to-left shunt across the iASD measuring 10x13mm in diameter. She declined to undergo a right and left heart study for further assessment of the iASD.

Percutaneous ASD closure was performed. Using TEE and fluoroscopy guidance, a 16mm Amplatzer septal occluder (ASO, Abbott Vascular, Redwood City, US) was successfully implanted. No oxygen or pressure measurements were made during the procedure as these findings would not have altered the treatment. There was no residual shunt and the oxygen saturation increased immediately from 89% to 96%. At 3-month follow-up, she reported marked symptom improvement (NYHA class II) and oxygen saturation was 98% on ambient air. Echocardiography showed unchanged LVEF and valve findings, and a stable ASO device with no residual interatrial shunt.

Fig. 1. (A) Transoesophageal echocardiographic image of the atrial septal defect (iASD) denoted by “+”. The shunt from the right atrium (RA) to the left atrium (LA) is demonstrated on colour Doppler (arrow). (B) 3-dimensional transoesophageal echocardiographic image of the iASD (arrow). (C) Transoesophageal echocardiographic image of the iASD after Amplatzer device closure. The white arrows denote the 2 discs straddling the interatrial septum and the yellow arrow denotes no residual shunt into the LA. (D) 3-dimensional transoesophageal echocardiographic image of the iASD after Amplatzer device closure. The arrows denotes the device disc viewed from the LA.

Discussion. Access to the left heart—from the femoral vein—via a transseptal puncture is necessary for percutaneous left heart structural interventions and for electrophysiology study and ablation of atrial fibrillation and LV VT. In most patients, the iASDs created close spontaneously or remain asymptomatic.1

Significant residual shunts usually occur after use of large bore devices such as with percutaneous mitral valve repair. It has been shown that up to 50% of patients have a residual iASD 6 months after transseptal access (22-French size sheath) for TMVr with the MitraClip system (Abbott Vascular, Redwood City, US).3 Persistent iASDs after transseptal access with smaller catheters such as electrophysiological procedures, BMV and LAAC are less common.1 Specifically, AF ablation requires 2 catheters in the left atrium (LA), achieved using either a single transseptal puncture with double cannulation, or a double transseptal puncture. Both are accepted techniques, but the single puncture technique demonstrated a slightly higher incidence of persistent iASDs, although the overall rate was low.4 Indeed, residual iASDs were detected in only 3.7–13.4% of patients 3–12 months after transseptal access for atrial fibrillation ablation,5-7 lower after RF ablation (2.4–8.5%) compared to cryoballoon ablation (16.7–22.2%).6,7 Furthermore, all iASDs after AF ablation were left-to-right shunts,5-7 and overall, only 2% of patients required device closure.7,8

Most iASDs that persist are fortunately haemodynamically insignificant; however, in some patients, left-to-right shunts result in progressive right ventricular overload and failure. Less commonly, right-to-left shunts result in arterial desaturation.1,2,9 Risk factors that predispose to persistent iASD include larger transseptal sheath size, procedure duration, amount of catheter manipulation while across the interatrial septum, lower LVEF, larger right atrial size, more severe MR and TR, as well as higher pulmonary artery, left and right atrial pressures.1,3,9 It has also been demonstrated that all defects <4mm closed and all defects >8mm persisted at 30 days post-procedure.10

Since most iASDs are benign or close spontaneously, and as there are risks associated with percutaneous closure (device erosion, device embolisation, device clot formation and difficulty in performing future transseptal procedures),2 routine closure is currently not recommended.1 However, large iASDs or shunts that result in heart failure or arterial desaturation will need to be closed. Percutaneous iASD closure is the treatment of choice given its minimally invasive nature and low periprocedural risks. Most case series demonstrate good clinical outcomes after device closure for symptomatic iASDs.2

It was likely that the iASD persisted in our patient due to the presence of most of the risk factors mentioned, including double transseptal cannulation, repeated catheter manipulations, prolonged procedure duration, lower LVEF, severely dilated RA, and significant MR and TR. As right-to-left shunts have not been reported after transseptal access for catheter ablation, we postulate that the right-to-left shunt in our patient was facilitated by the severe TR jet “directing” blood across the iASD into the LA.

In conclusion, this report demonstrates that a significant intertrial shunt can develop after transseptal access in procedures using “standard” EP catheters. This may be encountered more frequently in future as the volume of transseptal access for electrophysiological procedures and structural heart interventions increase. An interatrial shunt must be considered in any patient who develops dyspnoea or arterial desaturation after transseptal procedures. Percutaneous device closure is required for symptom relief and to prevent clinical deterioration.


  1. Matar F, Welter-Frost A. Management of Iatrogenic Atrial Septal Defects in the Era of Large-Bore Transcatheter Mitral Valve Therapies. Cardiovasc Revasc Med 2021;31:83-8.
  2. Chezar-Azerrad C, Assali A, Vaknin-Assa H, et al. Iatrogenic atrial septal defect post mitral valve in valve implantation. Cardiovasc Revasc Med 2018;19:82-5.
  3. Schueler R, Ozturk C, Wedekind JA, et al. Persistence of iatrogenic atrial septal defect after interventional mitral valve repair with the MitraClip system: a note of caution. JACC Cardiovasc Interv 2015;8:450-9.
  4. Naksuk N, Asirvatham SJ. Iatrogenic atrial septal defect: reassurance or inquisitiveness. J Interv Card Electrophysiol 2018;52:137-40.
  5. Rillig A, Meyerfeldt U, Birkemeyer R, et al. Persistent iatrogenic atrial septal defect after pulmonary vein isolation: incidence and clinical implications. J Interv Card Electrophysiol 2008;22:177-81.
  6. Mugnai G, Sieira J, Ciconte G, et al. One Year Incidence of Atrial Septal Defect after PV Isolation: A Comparison Between Conventional Radiofrequency and Cryoballoon Ablation. Pacing Clin Electrophysiol 2015;38:1049-57.
  7. Cronin EM, Collier P, Wazni OM, et al. Persistence of atrial septal defect after cryoballoon ablation of atrial fibrillation. J Am Coll Cardiol 2013;62:1491-2.
  8. Chan NY, Choy CC, Lau CL, et al. Persistent iatrogenic atrial septal defect after pulmonary vein isolation by cryoballoon: an under-recognized complication. Europace 2011;13:1406-10.
  9. Morikawa T, Miyasaka M, Flint N, et al. Right-to-Left Shunt Through Iatrogenic Atrial Septal Defect After MitraClip Procedure. JACC Cardiovasc Interv 2020;13:1544-53.
  10. Smith T, McGinty P, Bommer W, et al. Prevalence and echocardiographic features of iatrogenic atrial septal defect after catheter-based mitral valve repair with the MitraClip system. Catheter Cardiovasc Interv 2012;80:678-85.